Comparison of pharmacological properties of rubidomycine and its newly synthesized derivatives DR-22 and DR-27 in animals.
The effect of two newly synthesized 5-amino modified analogues of rubidomycine was submitted to preliminary pharmacological and histological investigations in healthy Albino Swiss mice. The results showed a similarity of the tested properties of the new compounds and commercial rubidomycine, suggesting the same spectrum undesired side-effects after acute administration. Of the two novel compounds DR-22 was found to be less toxic, while much potent in its action on the haematopoietic system in comparison to rubidomycine, in prolonged treatment. DR-22 is a candidate for further, more detailed investigations.
Kleinrok
Z
Z
Department of Pharmacology, School of Medicine, Lublin.
Chmielewska
B
B
Chibowski
D
D
Siezieniewska
Z
Z
Rajtar
G
G
Sawiniec
Z
Z
D000700:Analgesics; D000818:Animals; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000633:toxicity; D005260:Female; D006321:Heart / Q000187:drug effects; D006413:Hematopoietic System / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009206:Myocardium / Q000473:pathology
D000700:Analgesics; C056239:5-aminodaunorubicin; C056240:5-imino-N-(1-carboethoxypropen-1-yl)daunorubicin; D003630:Daunorubicin